Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis

Qinmei Xiong, Cen Wang, Hualong Liu, Zhaochong Tan, Chen Chen, Juxiang Li, Gregory Y H Lip, Kui Hong

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)
52 Downloads (Pure)

Abstract

There are few head-to-head trials directly comparing non-vitamin K antagonist oral anticoagulants (NOACs) against one other. A network meta-analysis (NMA) was performed to examine the indirect comparisons among NOACs in Asians with nonvalvular atrial fibrillation (NVAF). STATA 15.0 and ADDIS 1.16.8 softwares were used to perform the statistical analysis. Odds ratios with 95% credible intervals were applied to evaluate the end points. The probabilities of treatment rank were used to understand which interventions are more effective and safe, and the total rank probability was 1. In our NMA, the rank probabilities of apixaban in the case of stroke or systemic embolism, death from any cause, major bleeding, and intracranial hemorrhage (ICH) were 0.47, 0.49, 0.42, and 0.51, respectively. For cases of myocardial infarction, the rank probabilities of rivaroxaban were 0.40. This NMA indirectly compares the main efficacy and safety end points among NOACs in Asians with NVAF, and the rank probability analysis showed that apixaban likely performs best in cases of stroke or systemic embolism, death from any cause, and ICH; rivaroxaban may have the best performance for myocardial infarction.

Original languageEnglish
Article number1076029619885188
JournalClinical and Applied Thrombosis/Hemostasis
Volume25
ISSN1076-0296
DOIs
Publication statusPublished - 2019

Keywords

  • Asian
  • NOACs
  • atrial fibrillation
  • indirect comparison
  • network meta-analysis

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis'. Together they form a unique fingerprint.

Cite this